Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

NCT03267589

Name: Durvalumab and oleclumab in patients with relapsed ovarian cancer
Uploaded: 2021-10-24T00:00:00Z
Duration: 3 min 3 s
Description: Mansoor Raza Mirza, MD, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, discusses the findings of a Phase II NSGO-OV-UMB1/ENGOT-OV30 study evaluating durvalumab and oleclumab, a monoclonal antibody against CD73, in patients with relapsed ovarian cancer. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.

Sorry, no posts matched your criteria.

NCT03267589

Cookie settings